Log In
BCIQ
Print this Print this
 

GSK2998728, IONIS-TTRRx (formerly ISIS-TTRRx)

  Manage Alerts
Collapse Summary General Information
Company Ionis Pharmaceuticals Inc.
DescriptionTransthyretin (TTR) antisense inhibitor
Molecular Target Transthyretin (TTR)
Mechanism of ActionAntisense therapy
Therapeutic ModalityNucleic acid: Linear RNA: Antisense
Latest Stage of DevelopmentPhase III
Standard IndicationAmyloidosis
Indication DetailsTreat familial amyloid polyneuropathy (FAP); Treat transthyretin (TTR) amyloidosis; Treat transthyretin (TTR) familial amyloid polyneuropathy (FAP); Treat transthyretin (TTR)-related cardiomyopathy; Treat wild-type transthyretin (TTR) amyloidosis; Treat wild-typeTTR amyloidosis cardiomyopathy (TTRCM)
Regulatory Designation U.S. - Fast Track (Treat transthyretin (TTR) familial amyloid polyneuropathy (FAP));
U.S. - Fast Track (Treat transthyretin (TTR) amyloidosis);
U.S. - Orphan Drug (Treat transthyretin (TTR) amyloidosis);
EU - Orphan Drug (Treat transthyretin (TTR) amyloidosis)
PartnerGlaxoSmithKline plc

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$1,500.0M

$35.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

03/31/2010

$1,500.0M

$35.0M

Undisclosed

Get a free BioCentury trial today